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Introduction {#sec1}
============

The liver is central for the regulation of energy homeostasis, controlling several biochemical pathways important for metabolism of lipids, carbohydrates, proteins, bile synthesis, and detoxification of drugs and toxins. The liver also controls endocrine responses through the production of hepatokines. These proteins secreted by the hepatocytes act as hormones, and several hepatokines are considered promising leads for metabolic therapy development ([@bib23]). Among them, fibroblast growth factor 21 (FGF21) has emerged as an interesting target ([@bib28]). Originally targeted for its glucose-lowering properties in rodents and primates ([@bib5], [@bib13], [@bib29]), FGF21 is also able to improve insulin sensitivity and lipid homeostasis and induce weight loss ([@bib10], [@bib34]).

*Fgf21* is a direct target of the nuclear receptor peroxisome-proliferator-activated receptor α (PPARα) in response to fasting ([@bib2], [@bib33]). Activated by free fatty acids derived from lipolysis ([@bib24], [@bib36]), PPARα is essential to liver health, as its deletion promotes the development of non-alcoholic fatty liver disease (NAFLD) and hypercholesterolemia during aging ([@bib36]). The beneficial role of PPARα in response to dyslipidemia is thought to be mediated, at least in part, through FGF21 ([@bib37]). Indeed, anti-diabetic therapies and PPARα agonists (fenofibrate or Wy-14653) significantly induce liver-derived FGF21 in both mouse and human plasma ([@bib9], [@bib14], [@bib33]).

Hepatocyte PPARα plays an essential role during fasting, which triggers transcriptional regulation for the maintenance of glycemia and ketogenesis through fatty acid catabolism for use as an alternative energy source ([@bib17]). In agreement, PPARα-deficient mice exhibit impaired fatty acid oxidation and ketogenesis that promotes hepatic steatosis during fasting ([@bib27], [@bib30], [@bib31], [@bib36]).

Recent work reported that FGF21 is also activated in response to glucose and fructose in rodents and humans ([@bib18], [@bib19], [@bib41], [@bib44]). Enriched in liver, the transcription factor carbohydrate-responsive element-binding protein (ChREBP) mediates the response to dietary carbohydrates ([@bib1]). A physiological role for the ChREBP-FGF21 axis was revealed in experiments showing that in response to sugar consumption, ChREBP-enhanced FGF21 secretion from the liver blocked sugar-seeking behavior in mice and primates by targeting the paraventricular nucleus of the hypothalamus ([@bib43], [@bib46]). The ChREBP protein contains a low-glucose inhibitory domain (LID) and a glucose responsive activation conserved element (*GRACE*) located in its N terminus ([@bib32]). Activation of GRACE by glucose promotes ChREBP transcriptional activity and binding to the carbohydrate-responsive element (ChoRE) of its target genes, including L-pyruvate kinase (*Lpk*), a rate-limiting enzyme in glycolysis, fatty acid synthase (*Fas*), and steroyl CoA desaturase (*Scd1*), key enzymes of de novo lipogenesis ([@bib26]). Another isoform of *Chrebp*, *Chrebpβ*, originating from an alternative promoter, was identified in adipose tissue and liver ([@bib18]). This alternative splicing results in a constitutively active ChREBP isoform lacking the LID, a domain associated with inhibition of ChREBP activity ([@bib18]).

Understanding the regulation of FGF21 is currently a research focal point. Through the use of *Chrebp* knockout mice, we report here that ChREBP is required for the expression and secretion of hepatic FGF21 in response to carbohydrate intake. Unexpectedly, studies in hepatocyte-specific *Ppar*α knockout mice reveal a physiological role for PPARα in the context of glucose challenge, as ChREBP is unable to induce *Fgf21* in the absence of hepatic PPARα. Altogether, our results suggest that FGF21's glucose-mediated response is dependent on both ChREBP and PPARα.

Results {#sec2}
=======

FGF21 Is Induced by Both Fasting and Glucose Challenge {#sec2.1}
------------------------------------------------------

To characterize gene expression during fasting and a glucose challenge, a microarray analysis was conducted using liver samples from wild-type mice ([Figure 1](#fig1){ref-type="fig"}). Genes sensitive to glucose or fasting that were markedly different from the fed group were incorporated into a heatmap ([Figure 1](#fig1){ref-type="fig"}A). 67 genes were significantly induced by glucose in comparison to fed conditions (cluster 1), and 675 genes were significantly upregulated between fed and fasted groups (cluster 6). Gene ontology analysis revealed that pathways identified as specifically impacted by glucose and not by fasting are involved in pyruvate and insulin-sensitive metabolism ([Figure 1](#fig1){ref-type="fig"}B). Gene ontology revealed that pathways specifically sensitive to fasting, but not to glucose, are involved in PPAR signaling ([Figure 1](#fig1){ref-type="fig"}C). Interestingly, among the top genes upregulated by glucose and fasting ([Figure S1](#mmc1){ref-type="supplementary-material"}A), only 3 genes (*Fgf21*, *Fut1*, and *Atf5*) were significantly upregulated (log fold change \[FC\] \> 1; p ≤ 0.01) as compared to fed conditions ([Figure 1](#fig1){ref-type="fig"}D). When the stringency of the selection was increased to a log FC \> 2 ([Figure 1](#fig1){ref-type="fig"}E), *Fgf21* was left to be the sole gene upregulated by both fasting and glucose challenge (log FC = 3.9 and log FC = 3.7, respectively (p ≤ 0.01) ([Figure 1](#fig1){ref-type="fig"}E). qPCR analysis confirmed that *Fgf21* expression was significantly upregulated by fasting and glucose compared to fed conditions ([Figure 1](#fig1){ref-type="fig"}F). The glucose effect was validated through analysis of *Chrebp*, *Chrebpβ*, and *Lpk* gene expression, while the effect of fasting was assessed by measuring the expression of two typical PPARα targets, *Cyp4a10* and *Vnn1* ([Figure 1](#fig1){ref-type="fig"}F).Figure 1FGF21 Is Highly Induced by Both Fasting and Glucose ChallengeWild-type C57BL/6J 10-week-old male mice were fed ad libitum, fasted for 24 hr, or fed for 24 hr a standard diet with addition of 20% glucose in drinking water (glucose challenge). Mice were killed at ZT14 (14 hr after the start of light period in the animal housing unit). Transcriptomic analysis was performed on livers (n = 6 per condition) using gene expression microarray.(A) Heatmap of differentially expressed probes (false discovery rate \[FDR\] \< 5%).(B and C) KEGG categories corresponding to functions impacted by glucose (B) and fasting (C).(D) Venn diagram presenting the overlap between glucose- and fasting-induced gene expression (log FC \> 1; adjusted p \< 0.01).(E) Venn diagram presenting the overlap between glucose- and fasting-induced gene expression (log FC \> 2; adjusted p \< 0.01).(F) Gene expression determined by qPCR. Data are expressed as means ± SEM, n = 6 individual mice per group. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

ChREBP Is Necessary for Glucose-Mediated Expression and Secretion of Hepatic FGF21 {#sec2.2}
----------------------------------------------------------------------------------

To address the importance of ChREBP in the *Fgf21* glucose response, experiments were first performed in mouse hepatocytes from wild-type mice ([Figure 2](#fig2){ref-type="fig"}). We observed that *Fgf21* expression was induced by elevated glucose concentrations and paralleled with *Chrebp*, *Chrebpβ*, and target gene expression ([Figure 2](#fig2){ref-type="fig"}A). ChREBP recruitment onto the *Fgf21* and *Lpk* promoters significantly increased under high glucose concentrations (25 mM) ([Figure 2](#fig2){ref-type="fig"}B). This stimulatory effect of glucose was specific and not linked to an osmotic shock, since *Fgf21* expression was not induced in response to mannitol ([Figure S2](#mmc1){ref-type="supplementary-material"}). To determine whether ChREBP is mandatory for upregulation of FGF21 in response to glucose, experiments were completed in hepatocytes lacking ChREBP (*Chrebp*^−/−^) ([Figures 2](#fig2){ref-type="fig"}C--2E). Mice lacking exons 9--15 of the *Chrebp* gene were generated through homologous recombination ([Figure S3](#mmc1){ref-type="supplementary-material"}). The absence of the ChREBP protein (α isoform, 94 kDa) was validated in *Chrebp*^−/−^ hepatocytes by western blot analysis ([Figure 2](#fig2){ref-type="fig"}C). Under these conditions, the ChREBPβ protein (72 kDa) could not be detected (data not shown). Similarly to *Chrebp, Chrebpβ*, and the ChREBP and ChREBPβ target genes *Lpk* and *Scd1*, *Fgf21* robustly responded to 25 mM glucose stimulation in wild-type hepatocytes, but this response was blunted in *Chrebp*^−/−^ hepatocytes ([Figure 2](#fig2){ref-type="fig"}D). In addition, no increase in FGF21 in culture medium was detected when *Chrebp*^−/−^ hepatocytes were cultured in 25 mM glucose ([Figure 2](#fig2){ref-type="fig"}E). Of note, basal FGF21 production (5 mM glucose) was also significantly decreased in culture medium from *Chrebp*^−/−^ hepatocytes ([Figure 2](#fig2){ref-type="fig"}E). These findings indicate that ChREBP is mandatory for the glucose-mediated expression and secretion of FGF21 by hepatocytes.Figure 2ChREBP Is Necessary for Glucose-Mediated Expression and Secretion of FGF21 In Vitro(A and B) Hepatocytes prepared from male C57BL/6J mouse livers were stimulated 1 day after platting for 24 hr with medium containing 5, 10, 15, 20, 25, or 30 mM glucose. (A) qPCR analysis of *Fgf21*, *Chrebp, Chrebpβ, Lpk*, and *Scd1* gene expression. Data are presented as means ± SEM from 4 independent cultures done in triplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). (B) ChIP analysis for ChREBP binding on the *Fgf21* and *Lpk* ChoRE followed by qPCR in mouse hepatocytes challenged with 5 or 25 mM glucose for 24 hr. Data are expressed as means ± SEM (n = 3). Significance is based on Student's t test followed by Mann-Whitney post hoc test (^∗^p \< 0.05).(C--E) Primary hepatocytes from female *Chrebp*^−/−^ and *Chrebp^+/+^* littermates were stimulated 1 day after platting for 24 hr with cell culture medium containing 5 or 25 mM glucose. (C) Western blot analysis of protein from whole hepatocyte lysate. Two representative samples are presented. β actin was used as loading control. (D) Gene expression determined by qPCR. (E) ELISA quantification of FGF21 protein in medium collected at the end of glucose stimulation.Data are presented as means ± SEM from 4 independent cultures in triplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001).

Liver-Specific ChREBP Expression Rescues FGF21 Plasma Concentrations in ChREBP Knockout Mice {#sec2.3}
--------------------------------------------------------------------------------------------

We next performed glucose challenge experiments in vivo. 10- to 12-week-old *Chrebp*^+/+^ and *Chrebp*^−/−^ male mice were given 24-hr access to a bottle of glucose-free water (fed) or a bottle containing 20% glucose (glucose challenge) ([Figure 3](#fig3){ref-type="fig"}). A significant elevation in blood glucose was observed in glucose-challenged *Chrebp*^−/−^ mice compared to *Chrebp*^+/+^ mice under the same conditions ([Figure 3](#fig3){ref-type="fig"}A). A trend toward higher insulin concentrations was observed in *Chrebp*^−/−^ mice compared to controls (under fed and glucose conditions), but this difference did not reach statistical significance ([Figure 3](#fig3){ref-type="fig"}B). Glucose challenge raised ChREBP protein content in liver of *Chrebp*^+/+^ mice ([Figure 3](#fig3){ref-type="fig"}C). A significant stimulation in hepatic triglyceride (TG) concentrations was also observed in glucose-challenged *Chrebp*^+/+^ mice, but not *Chrebp*^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}D). A significant increase in *Chrebp*, *Chrebpβ*, *Lpk*, and *Scd1* mRNA levels was observed in liver of glucose-challenged *Chrebp*^+/+^ mice compared to fed mice from the same genotype ([Figure 3](#fig3){ref-type="fig"}E). *Fgf21* mRNA and plasmatic FGF21 protein concentrations markedly increased in glucose-challenged *Chrebp*^+/+^ mice. While a residual (nonsignificant) glucose effect was observed in *Chrebp*^−/−^ mice, this response was significantly reduced compared to *Chrebp*^+/+^ mice ([Figures 3](#fig3){ref-type="fig"}F and 3G), despite elevated blood glucose levels ([Figure 3](#fig3){ref-type="fig"}A). These results show that ChREBP is required for the in vivo glucose-mediated induction of *Fgf21*.Figure 3FGF21 Is Unable to Respond to a Glucose Challenge without ChREBP(A--G) Adult male *Chrebp*^−/−^ and *Chrebp*^+/+^ littermates were allowed access to a 20% glucose drinking water solution and standard chow diet ad libitum for 18 hr. Fed mice received drinking water from the same water source used to make the glucose solution. (A) Blood glucose (mg/dl) recovered at the time of harvest from tail snip. (B) Insulin concentrations (ng/ml). (C) Western blot analysis of protein from whole liver lysate. β actin was used as loading control. Three representative samples are presented. (D) Hepatic triglyceride (TG) concentrations. Relative *Chrebp*, *Chrebpβ*, *Lpk*, and *Scd1* gene expression (E) and *Fgf*21 (F) gene expression determined by qPCR. (G) ELISA quantification of FGF21 protein (ng/mL) in plasma. Data are presented as means ± SEM from 6 to 8 individual mice. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; nd, not detectable).(H--J) Adult male *Chrebp*^+/+^ and *Chrebp*^−/−^ mice were injected intravenously with a single dose of 3 × 10^9^ pfu GFP or ChREBP^CA^ adenovirus on day 1. Four days later, analyses were performed. (H) Blood glucose (mg/dl) recovered at the time of harvest from tail snip. (I) Western blot analysis of protein extracted from whole liver lysate. β actin was used as loading control. Three representative samples are presented. (J) ELISA quantification of FGF21 protein (ng/ml) in plasma.(K) Relative expression of hepatic genes determined by qPCR.Data are presented as means ± SEM from 8 to 12 individual mice. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; nd, not detectable).

We next addressed whether liver-specific re-expression of *Chrebp* in a context of global ChREBP deficiency could rescue FGF21 production. *Chrebp*^+/+^ and *Chrebp*^−/−^ adult mice were injected with an adenovirus vehicle containing the GFP protein or a truncated isoform of ChREBP lacking the LID domain ([@bib32]) corresponding to a constitutively active ChREBP isoform (ChREBP^CA^). Mice received a 20% glucose solution for 24 hr before sacrifice ([Figures 3](#fig3){ref-type="fig"}H--3K). Blood glucose concentrations were higher in GFP-ChREBP^−/−^ mice than in GFP-ChREBP^+/+^ mice and were rescued to basal values when ChREBP^CA^ was injected into *Chrebp*^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}H). Western blot analysis confirmed the absence of native ChREBP protein (94 kDa) but the presence of ChREBP^CA^ (72 kDa) in *Chrebp*^−/−^ mice injected with ChREBP^CA^ ([Figure 3](#fig3){ref-type="fig"}I). Importantly, ChREBP^CA^ rescued the circulating level of FGF21 ([Figure 3](#fig3){ref-type="fig"}J). This correlates with the effect of ChREBP^CA^ on the hepatic expression of *Chrebp*, *Chrebpβ*, and their targets, *Lpk, Scd1*, and *Fgf21* mRNA ([Figure 3](#fig3){ref-type="fig"}K). Altogether, we report that ChREBP^CA^ administration rescued ChREBP activity in the liver of *Chrebp*^−/−^ mice and was sufficient to restore FGF21 gene expression and production.

Glucose Stimulation or ChREBP Overexpression Is Not Efficient to Induce FGF21 Expression or Secretion in the Absence of Hepatic PPARα {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------

Since the *Fgf21* promoter contains overlapping peroxisome proliferator response element (PPRE) and ChoRE units (−88 to −54 bp) ([@bib16], [@bib44]), we investigated whether PPARα could impact the glucose response of *Fgf21* mediated by *Chrebp*. Primary hepatocytes from liver-specific *Pparα* knockout mice (*Ppar*α^hep−/−^) and their littermates, *Pparα*^hep +/+^ mice ([@bib36]), were stimulated by glucose in a dose-dependent manner ([Figure 4](#fig4){ref-type="fig"}). A similar glucose-mediated induction of *Chrebp*, *Chrebpβ*, *Lpk*, and *Scd1* mRNA was observed in hepatocytes from *Pparα*^hep +/+^ and *Pparα*^hep\ −/−^ mice ([Figure 4](#fig4){ref-type="fig"}A). Although a residual glucose effect was observed for *Fgf21* expression in *Pppaα*^hep\ −/−^ mice hepatocytes, this response was reduced compared to *Pparα*^hep+/+^ mice ([Figure 4](#fig4){ref-type="fig"}B). Importantly, FGF21 production in response to glucose was reduced by 60% in culture medium from *Pppaα*^hep−/−^ hepatocytes compared to controls ([Figure 4](#fig4){ref-type="fig"}C). This profile was specific to *Fgf21*, since the expression of other typical PPARα targets (*Cyp4a10*, *Cyp4a14*, or *Vnn1*) was not induced by glucose ([Figure S4](#mmc1){ref-type="supplementary-material"}). We next addressed whether *Fgf21* could be rescued by *Chrebp* overexpression in the context of *Pparα* deficiency. Hepatocytes from *Pparα*^hep+/+^ and *Pppaα*^hep\ −/−^ mice were infected with the constitutive active form of ChREBP (ChREBP^CA^) for 24 hr. The expression of *Chrebp* and *Chrebpβ* was significantly increased in response to ChREBP^CA^ in both *Pparα* ^hep+/+^ and *Pppaα*^hep\ −/−^ hepatocytes, and as a result, *Lpk* and *Scd1* mRNA expression was stimulated compared to GFP conditions ([Figure 4](#fig4){ref-type="fig"}D). However, while *Chrebp* overexpression led to a 50-fold increase in *Fgf21* expression in *Pparα*^hep+/+^ hepatocytes, it failed to significantly induce *Fgf21* expression in *Pppaα*^hep\ −/−^ hepatocytes ([Figure 4](#fig4){ref-type="fig"}E). FGF21 measured in the medium of cell culture confirmed the *Fgf21* mRNA expression profile ([Figure 4](#fig4){ref-type="fig"}F). These results suggest that neither glucose nor ChREBP overexpression is efficient in inducing *Fgf21* gene expression or protein production in the absence of PPARα in hepatocytes.Figure 4*Fgf21* Is Not Efficiently Induced by Glucose or by ChREBP Overexpression in the Absence of Liver PPARα(A--C) Primary hepatocytes derived from adult male *Pparα*^hep+/+^ or *Pparα*^hep−/−^ mice were incubated 1 day after platting for 24 hr with medium containing 5, 10, 15, 20, 25, or 30 mM glucose. Relative *Chrebp, Chrebpβ*, *Lpk*, and *Scd1* gene expression (A) and *Fgf*21 gene expression (B) was determined by qPCR. (C) ELISA quantification of FGF21 protein (ng/ml) in medium collected at end of glucose stimulation. Figures are presented as means ± SEM from 4 independent cultures completed in duplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; nd, not detectable).(D--F) Primary hepatocytes derived from adult male mice *Pparα*^hep+/+^ or *Pparα*^hep−/−^ were incubated 6 hr after platting with 3 × 10^9^ pfu GFP or ChREBP^CA^ adenovirus at a glucose concentration of 5 mM for 24 hr. Relative *Chrebp*, *Chrebpβ*, *Lpk*, and *Scd1* expression (D) and of *Fgf*21 expression (E) was determined by qPCR. (F) ELISA quantification of FGF21 protein (in ng/ml) in medium collected at end of adenoviral treatment.Data are presented as means ± SEM from 4 independent cultures completed in duplicate. Significance is based on two-way ANOVA followed by a Bonferroni post hoc test (^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001).

FGF21 Synergistically Responds to Glucose and a Pharmacological PPARα Activator in Both Mouse and Human Hepatocytes {#sec2.5}
-------------------------------------------------------------------------------------------------------------------

To determine whether ChREBP and PPARα act in synergy to regulate *Fgf21* gene expression, mouse and human hepatocytes were stimulated for 24 hr with low (5 mM) or high glucose concentrations (25 mM) in the presence of the PPARα agonist Wy-14643 ([Figure S5](#mmc1){ref-type="supplementary-material"}). Expression of *Chrebp* and *Chrebpβ* mRNA confirmed a positive glucose response in both mouse and human hepatocytes ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Activation of PPARα by Wy-14643 was validated by a significant upregulation in *Acox1* expression, a PPARα target gene ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). *Fgf21* mRNA levels were drastically increased when hepatocytes (mouse and human) were incubated in the combined presence of high glucose (25 mM) and Wy-14643 ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). Altogether, these results show that ChREBP and PPARα can act synergistically to induce *Fgf21* in mouse and in human liver cells.

Hepatocyte PPARα Is Required for the Effect of Glucose on FGF21 In Vivo {#sec2.6}
-----------------------------------------------------------------------

To investigate whether PPARα is involved in the glucose-mediated induction of *Fgf21* in vivo, glucose challenge experiments were performed in 10- to 12-week-old *Pparα*^hep+/+^ and *Pparα* ^hep−/−^ mice. Three nutritional conditions were assigned to both genotypes: (1) mice fasted 24 hr with free access to water (fasted), (2) mice fed ad libitum with access to standard chow diet and free access to water (fed), and (3) mice fed ad libitum with access to standard chow diet and a 20% glucose solution in water (glucose challenge) ([Figure 5](#fig5){ref-type="fig"}). *Chrebp*, *Chrebpβ*, and their target genes (*Lpk* and *Scd1*) were induced in a similar manner in the liver of *Pparα* ^hep+/+^ and *Pparα*^hep−/−^ mice when challenged by glucose ([Figure 5](#fig5){ref-type="fig"}A). In contrast, the glucose-mediated induction of *Fgf21* (compared to the fed state) was significantly reduced in the absence of PPARα ([Figure 5](#fig5){ref-type="fig"}A). FGF21 in the circulation matched hepatic mRNA levels, revealing an upregulation of FGF21 in the plasma of *Pparα* ^hep+/+^ that was significantly reduced in glucose-challenged *Pparα*^hep−/−^ mice ([Figure 5](#fig5){ref-type="fig"}B). As expected, loss of PPARα markedly impacted the fasting response of FGF21 ([Figure 5](#fig5){ref-type="fig"}A-B). Because the *Fgf21* promoter contains overlapping PPRE and ChoRE units ([Figure 5](#fig5){ref-type="fig"}C), we investigated whether lack of PPARα could impair ChREBP binding in response to glucose in vivo. When primers amplifying both ChoRE and PPRE were used ([Figure 5](#fig5){ref-type="fig"}C), a significant enrichment in PPARα binding within the proximal region of the *Fgf21* promoter in liver of *Pparα* ^hep+/+^ mice was observed ([Figure 5](#fig5){ref-type="fig"}D). While PPARα binding was elevated under fasting conditions, a significant PPARα recruitment onto the proximal region of the *Fgf21* promoter was detected under both fed and glucose-challenge conditions ([Figure 5](#fig5){ref-type="fig"}D). Surprisingly, in liver of glucose challenged *Pparα* ^hep−/−^ mice, recruitment of ChREBP on the *Fgf21* promoter ChoRE was significantly reduced ([Figure 5](#fig5){ref-type="fig"}D). Interestingly, a significant decrease in RNA polymerase II (Pol II) recruitment and histone H3 lysine 9 acetylation (H3K9ac), a histone mark related to transcriptional activation, was observed in parallel in the liver of these mice ([Figure 5](#fig5){ref-type="fig"}D). In contrast, ChREBP recruitment on the *Lpk* ChoRE was similar in glucose-challenged *Pparα*^hep+/+^ and *Pparα*^hep\ −/−^ mice ([Figure 5](#fig5){ref-type="fig"}E). The presence of Pol II on the *Lpk* promoter ([Figure 5](#fig5){ref-type="fig"}E) was significantly elevated in response to glucose in liver of mice from both genotypes and correlated with *Lpk* mRNA expression ([Figure 5](#fig5){ref-type="fig"}A). Altogether, our results show that the absence of PPARα impairs the binding of ChREBP to its ChoRE and the subsequent glucose-mediated induction of *Fgf21*. Surprisingly, significant ChREBP recruitment was also detected on the *Fgf21* ChoRE under fasting conditions ([Figure 5](#fig5){ref-type="fig"}D). Further analysis will be required to determine whether ChREBP interferes with the fasting-mediated induction of *Fgf21* expression in the liver, as suggested in a recent report showing that liver-specific *Chrebp* knockout mice have decreased *Fgf21* expression compared to controls ([@bib25]).Figure 5PPARα Is Required for the Glucose-Dependent Expression and Secretion of FGF21 by the LiverMale *Pparα*^hep+/+^ or *Pparα*^hep−/−^ mice were assigned one of three treatment groups: (1) fasted 24 hr with free access to drinking water (fasted), (2) fed ad libitum with free access to drinking water (fed), or (3) fed ad libitum with access to a 20% glucose drinking water solution for 24 hr (glucose challenge).(A) Relative gene expression of *Chrebp*, *Chrebpβ*, *Lpk*, *Scd1*, and *Fgf21* was determined by qPCR. Data are expressed as means ± SEM (n = 6 individual mice per group). Significance is based on two-way ANOVA followed by Bonferroni post hoc test (fasting or glucose versus fed; \#p ≤ 0.05; \#\#p ≤ 0.01; \#\#\#p ≤ 0.001). Significance of the effect of genotype is based two-way ANOVA followed by Bonferroni post hoc test (*Pparα*^hep−/−^ versus *Pparα*^hep +/+^; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001).(B) ELISA quantification of FGF21 in plasma. Data are expressed as means ± SEM from n = 6 individual mice per group. Significance of the effect of fasting or glucose challenge is based on two-way ANOVA followed by post hoc test (fasting or glucose versus fed; \#p ≤ 0.05; \#\#p ≤ 0.01; \#\#\#p ≤ 0.001). Significance of the effect of genotype is based on two-way ANOVA followed by Bonferroni post hoc test (*Pparα*^hep−/−^ versus *Pparα*^hep +/+^; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001).(C) *Fgf21* promoter sequence from the transcription start site to −184 bp. The PPARα binding site (PPRE) is indicated in gray. The ChREBP binding site (ChoRE) is indicated in yellow. Primers used for ChIP analysis are indicated on the sequence.(D) ChIP analysis followed by qPCR of whole mouse liver tissue. Immunoprecipitation (IP) was conducted with PPARα, ChREBP, H3K9ac, and RNA Pol II antibodies. The DNA region of the *Fgf21* promoter was amplified using the primers indicated in (C).(E) ChIP analysis followed by qPCR of whole mouse liver tissue. IP were conducted with ChREBP and RNA Pol II antibodies. Data are expressed as means ± SEM from n = 3 individual mice per group. Significance is based on two-way ANOVA followed by Bonferroni post hoc test (^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001).

### Fgf21 Promoter Accessibility Is Reduced in the Absence of PPARα {#sec2.6.1}

To provide insights into the mechanisms by which PPARα affects ChREBP binding onto the *Fgf21* promoter in response to glucose, a series of experiments were conducted in vitro ([Figure 6](#fig6){ref-type="fig"}). First, we performed formaldehyde-assisted isolation of regulatory elements (FAIRE)-qPCR analysis ([@bib42]) to determine whether ChREBP accessibility to the *Fgf21* promoter could be altered in the absence of PPARα ([Figure 6](#fig6){ref-type="fig"}A). We observed that while *Fgf21* ChoRE promoter accessibility tended to increase in response to high glucose concentrations in *Pparα* ^hep+/+^ hepatocytes, it failed to increase in *Pparα* ^hep−/−^ hepatocytes ([Figure 6](#fig6){ref-type="fig"}A). To get insight into the molecular mechanisms involved, we hypothesized that PPARα could affect ChoRE accessibility through epigenetic processes and tested whether a pan-histone deacetylase (pan-HDAC) inhibitor ([@bib21]) could increase *Fgf21* promoter accessibility. Treatment of hepatocytes with a HDAC inhibitor further enhanced the difference observed in *Fgf21* accessibility between *Pparα*^hep+/+^ and *Pparα*^hep−/−^ hepatocytes ([Figure 6](#fig6){ref-type="fig"}A), which correlated with a potentiated effect of glucose on *Fgf21* expression ([Figure 6](#fig6){ref-type="fig"}B). While no significant change in *Fgf21* promoter accessibility was observed in *Pparα*^hep\ −/−^ hepatocytes treated with the HDAC inhibitor ([Figure 6](#fig6){ref-type="fig"}A), a modest but significant effect was observed for *Fgf21* mRNA levels measured under these conditions. However, treatment failed to fully rescue *Fgf21* gene expression to control levels ([Figure 6](#fig6){ref-type="fig"}B). These data suggest that *Fgf21* promoter accessibility at the ChoRE is altered in the absence of PPARα by a mechanism that may partly rely on histone acetylation. To determine whether the potentiating effect of the HDAC inhibitor on glucose-induced *Fgf21* expression was due to enhanced ChREBP activity, experiments were performed in *Chrebp*^+/+^ and *Chrebp*^−/−^ hepatocytes ([Figure 6](#fig6){ref-type="fig"}C). Similar to what was observed in *Pparα*^hep+/+^ hepatocytes ([Figure 6](#fig6){ref-type="fig"}B), the effect of glucose (25 mM) on *Fgf21* expression was increased when *Chrebp*^+/+^ hepatocytes were treated with the HDAC inhibitor ([Figure 6](#fig6){ref-type="fig"}C). *Chrebp*, *Chrebpβ*, and *Lpk* followed a similar trend, with a significant effect observed for *Chrebp* ([Figure 6](#fig6){ref-type="fig"}C). Importantly, the potentiated effect of the HDAC inhibitor on *Fgf21* expression was lost in *Chrebp*^−/−^ hepatocytes ([Figure 6](#fig6){ref-type="fig"}C), indicating a dependence on ChREBP activity. Altogether, our results suggest that PPARα is essential to allow ChREBP to gain access to the promoter of *Fgf21*. Moreover, our data show that the use of HDAC inhibitors enhances the ChREBP-dependent effect of glucose on *Fgf21* but cannot fully rescue the effect of PPARα deficiency.Figure 6*Fgf21* Promoter Accessibility Is Reduced in the Absence of PPARα(A and B) Primary hepatocytes derived from adult *Pparα*^hep+/+^ or *Pparα*^hep−/−^ mice were treated with 10 μM of the HADC inhibitor LBH589 or DMSO as a control for 24 hr in the presence of 5 or 25 mM glucose. (A) FAIRE-qPCR was performed as described in [Experimental Procedures](#sec4){ref-type="sec"}. (B) Fgf21 gene expression determined by qPCR. Data are presented as means ± SEM from 4 independent cultures performed in duplicate. Significance is based on two-way ANOVA followed by Bonferroni post hoc test (^∗^p % 0.05; ^∗∗^p % 0.01; ^∗∗∗^p % 0.001).(C) Primary hepatocyte derived from adult *Chrebp*^+/+^ or *Chrebp*^−/−^ mice were treated with 10 μM of the HADC inhibitor LBH589 or with DMSO as control for 24 hr in the presence of medium containing 5 or 25 mM glucose. Relative gene expression of *Chrebp*, *Chrebpβ*, *Lpk*, and *Fgf21* was determined by qPCR.Data are presented as means ± SEM from 4 independent cultures performed in duplicate. Significance is based on two-way ANOVA followed by Bonferroni post hoc test (^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001).

### Sucrose Intake Is Increased in Mice Lacking PPARα in the Liver {#sec2.6.2}

Finally, we determined whether the decrease in circulating FGF21 observed in glucose-challenged *Pparα* ^hep−/−^ mice ([Figure 5](#fig5){ref-type="fig"}B) paralleled with an increase in sucrose preference, since it was recently demonstrated that FGF21's action on the paraventricular nucleus of the hypothalamus blocks sugar-seeking behavior and sugar intake in mice ([@bib43], [@bib46]). First, we observed that there was no change in body weight or food or water intake in *Pparα* ^hep−/−^ compared to *Pparα* ^hep+/+^ mice fed with standard chow ([Figures 7](#fig7){ref-type="fig"}A--7C). Sucrose preference was then evaluated by giving *Pparα* ^hep+/+^ and *Pparα* ^hep+/+^ littermates matched for age and body weight free choice between a bottle containing a 10% sucrose solution and water ([Figure 7](#fig7){ref-type="fig"}D). Consumption, which was measured daily for 3 days, demonstrated that *Pparα* ^hep−/−^ mice consumed 30% more sucrose solution than *Pparα* ^hep+/+^ mice, while the volume of water drunk remained similar between genotypes ([Figure 7](#fig7){ref-type="fig"}E).Figure 7Sucrose Intake Is Increased in *Pparα*^hep−/−^ Mice(A--C) Average body weight gain (A), food (B) and water (C) intake of age-matched *Pparα*^hep+/+−^ and *Pparα*^hep−/−^ mice (n = 12/group) over 6 weeks.(D) Average body weight of age-matched male *Pparα*^hep+/+^ and *Pparα*^hep−/−^ mice used for the sucrose preference test (n = 16/group).(E) *Pparα*^hep+/+^ and *Pparα*^hep−/−^ mice were given a 4-day adaptation period with two water bottles. A 10% sucrose solution was added to one of the water bottles for 3 days following adaptation and intake of sucrose solution and water was recorded daily for 3 days. Data are presented as means ± SEM from 5 to 6 individual mice. Significance is based on 2-way ANOVA followed by Bonferroni post hoc test (^∗∗^p ≤ 0.01).

Discussion {#sec3}
==========

The regulation of FGF21 in the liver is complex due to the paradoxical regulation of this key hepatokine by fasting and glucose signals. In the current study, we uncovered a cross-talk between ChREBP and PPARα for the induction of hepatic FGF21 in response to a glucose challenge. The main finding of our study is that hepatic PPARα is necessary for the glucose-mediated induction of *Fgf21* by ChREBP.

Key to β-oxidation and ketogenesis, FGF21 mobilizes energy in the liver for peripheral use, protecting against dyslipidemia and hepatosteatosis ([@bib22], [@bib39]). First described as a fasting hormone regulated by PPARα, transcriptional regulation of *Fgf21* in the context of excessive blood glucose has only recently been explored ([@bib43], [@bib46]), despite early identification of the glucose-sensing region, ChoRE, on the *Fgf21* promoter in both mouse (−74 to −52 bp) and human (−380 to −366 bp) ([@bib19]). Our experiments confirm that FGF21 is significantly expressed and released by cultured mouse and human hepatocytes in response to glucose upon ChREBP binding to the ChoRE ([@bib19], [@bib44]). Our study demonstrates that deletion of ChREBP blunts transcription and secretion of hepatic FGF21 in response to glucose. Importantly, hepatic rescue of ChREBP in global ChREBP knockout mice is sufficient to restore *Fgf21* mRNA in the liver and protein in circulation, demonstrating the specificity of hepatic ChREBP activity on the induction of FGF21 in response to a glucose challenge. Interestingly, ChREBP rescue in the liver of *Chrebp^−/−^* mice significantly normalized blood glucose concentrations to control levels. This suggests that hepatic ChREBP activity and not peripheral ChREBP is essential for glucose-homeostasis maintenance. This result is consistent with a previous study in which hepatic ChREBP overexpression improved impaired glucose tolerance of high-fat-diet-challenged mice ([@bib3]) and is in agreement with a recent study reporting that liver *Chrebp* knockout mice exhibit impaired insulin sensitivity and glucose intolerance ([@bib25]). In this study, while hepatic *Chrebp* deletion protected against hepatic steatosis, it also resulted in gene expression changes in white and brown adipose tissues, suggesting inter-organ communication. The contribution of ChREBP to whole-body energy balance may therefore rely on its regulation of lipid species and/or hepatokine production that could contribute to inter-tissue coordination of energy homeostasis.

Activated in response to free fatty acids liberated from adipocytes during fasting ([@bib36]), a role for hepatocyte PPARα in the response to glucose had not yet been identified. Our study reveals that the synergic induction of *Fgf21* by glucose and the PPARα agonist Wy-14643 occurs in both mouse and human hepatocytes. We hypothesize that this cross-talk is specific to *Fgf21*, as we found no effect of glucose on other typical PPARα target genes. This *Fgf21* specificity may be due to the proximity of ChREBP- and PPARα-binding sites on the *Fgf21* proximal promoter, as both a PPRE and a ChoRE region coexist (−88 to −54 bp) ([@bib16]). Microarray analysis comparing gene regulation during fasting and glucose challenge highlights a small subset of genes that are upregulated in both conditions. Of those genes *Fgf21* is the most significantly induced. Therefore, FGF21 is a unique hepatic hormone showing dual regulation by fasting and carbohydrate signaling. Few publications have proposed a dialog between ChREBP and PPARs for the coordination of energy metabolism. Some examples of cross-talk and regulatory mechanisms have been described for lipid metabolism in brown adipose ([@bib20]) and pancreatic β cell function ([@bib6]). In the liver, it was also described that the PPARα co-factor PPAR γ coactivator-1β (PGC-1β) can act as a co-activator of ChREBP in response to glucose. PGC-1β is known to activate genes responsible for fatty acid oxidation and hepatic gluconeogenesis during fasting ([@bib45], [@bib48]), and it was also reported to upregulate de novo lipogenic genes during glucose stimulation in a ChREBP-dependent manner ([@bib8]). Altogether, these studies strongly suggest a direct and/or indirect interaction between ChREBP and the PPAR nuclear receptor family.

Here, we reveal a ChREBP-PPARα dialog in hepatocytes required for the induction of *Fgf21* by glucose. Indeed, despite normal hepatic ChREBP activity toward glycolytic and lipogenic genes, we report that in the absence of PPARα, ChREBP binding to the *Fgf21* ChoRE is significantly reduced, suggesting that hepatocyte PPARα is necessary for the ChREBP-mediated induction of *Fgf21* in response to glucose. Our study also reports that *Fgf21* promoter accessibility is reduced in the absence of PPARα. Deficient recruitment of ChREBP as well as Pol II was observed at the proximal *Fgf21* promoter locus under elevated glucose conditions in the liver of mice lacking hepatocyte PPARα. The fact that epigenetic marks (i.e., H3K9ac) of active transcription were reduced at the *Fgf21* promoter when PPARα was lacking in liver, under both fasting and glucose conditions, also supports the hypothesis of reduced promoter accessibility. Indeed, even under conditions of ChREBP overexpression, *Fgf21* expression was not efficiently induced in the context of PPARα deficiency. Further experiments will be needed to determine whether PPARα acts as a "pioneer" transcription factor for *Fgf21* transcription. Among several described functions, pioneer factors can trigger the opening and/or organization of the local chromatin, in turn allowing the binding of other transcription factors, histone-modification enzymes, chromatin modifiers, and/or nucleosome remodelers ([@bib49]). Of note, an HDAC inhibitor potentiated a ChREBP-dependent effect of glucose on *Fgf21* expression in primary hepatocytes. The HDAC inhibitor strategy in glucose-challenged PPARα-deficient hepatocytes only led to a modest restoration of *FgF21* expression. While this approach was not sufficient to fully restore accessibility to the *Fgf21* promoter, it does suggest that *Fgf21* promoter accessibility at the ChoRE is altered in the absence of PPARα by a mechanism that may partly rely on histone acetylation. We employed FAIRE-qPCR analysis to determine *Fgf21* promoter accessibility in response to glucose. A more sensitive approach, the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) ([@bib7]) may have allowed us to determine whether *Fgf21* promoter accessibility is indeed modified by an HDAC inhibitor strategy in *Pparα*^hep−/−^ hepatocytes. While other molecular mechanisms are clearly involved, the implication of specific HDACs should be further investigated, since it was recently shown that PPARα prevents the recruitment of HDAC3 to the *Fgf21* promoter in hepatocytes when concentrations of β-hydroxybutyrate, a key product of β-oxidation, are elevated ([@bib40]).

At the physiological level, we observed that *Pparα*^hep−/−^ mice consumed more sucrose (+30%) than *Pparα*^hep+/+^ mice. Two studies have recently unraveled the mechanistic link between sucrose-derived FGF21 and nutrient preference ([@bib43], [@bib46]). FGF21 production in response to carbohydrates was shown to markedly reduce sweet taste preference and suppress consumption of simple sugars by acting on specific regions of the brain ([@bib43], [@bib46]). In these studies, hepatic FGF21 production in response to carbohydrate intake was attributed to ChREBP activity. The fact that PPARα is also involved in this liver-to-brain axis following simple sugar consumption opens new molecular path of regulation of macronutrient preference/intake and expands liver PPARα function from a fasting regulator to a modulator affecting the physiological sugar response.

In conclusion, we identify a transcriptional node in the control of hepatic FGF21 in response to glucose. The glucose sensor ChREBP requires PPARα for the induction of FGF21 in response to dietary sugar. This is a unique collaboration between transcription factors that are activated in response to distinct nutritional conditions (high glucose for ChREBP and fasting for PPARα). These data imply that drug targeting of PPARα may exert part of its beneficial effects on metabolic homeostasis by supporting the ChREBP-induced loop controlling sweet preference via FGF21.

Experimental Procedures {#sec4}
=======================

Generation of ChREBP Knockout Mice {#sec4.1}
----------------------------------

Mice lacking exons 9--15 of the *Chrebp* gene were generated through homologous recombination. Correspondence regarding *Chrebp*^−/−^ mice should be addressed to R.D. (<renaud.dentin@inserm.fr>) and C.P. (<catherine.postic@inserm.fr>). Experimental details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Animals {#sec4.2}
-------

10- to 12-week-old adult male C57BL/6J, *Chrebp*^+/+^, *Chrebp*^−/−^, *Pparα*^hep+/+^, and *Pparα*^hep−/−^ mice ([@bib36]) were used for all in vivo experiments. For hepatocyte cultures, male and female mice were used as described in the figure legends. Procedures were carried out according to the French guidelines for the care and use of experimental animals (animal authorization agreement number CEEA34.AFB/CP.082.12, Paris Descartes Ethical Committee). Mice were maintained in a 12-hr light/dark cycle with water and a standard diet (65% carbohydrate, 11% fat, and 24% protein) unless otherwise specified. Nutritional challenges details are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Injection of Adenovirus In Vivo {#sec4.3}
-------------------------------

Adenovirus coding GFP and ChREBP^CA^ (ChREBP isoform deleted of the LID domain) ([@bib32]) produced by Laboratoire de thérapie génique (Nantes, France; requests to R.D. at <renaud.dentin@inserm.fr>) were delivered through penis vein injection (3 × 10^9^ \[pfu\]/mouse) to adult mice. Four days later, nutritional protocols were applied.

Primary Cultures of Human and Mouse Hepatocytes {#sec4.4}
-----------------------------------------------

Human hepatocytes were prepared from lobectomy segments resected from adult patients under the approval of the National Ethics Committee as described previously ([@bib38], [@bib35]). Mouse hepatocytes were isolated as described previously ([@bib11]). Experimental details regarding culture conditions are provided in the figure legends and [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP Analysis {#sec4.5}
-------------

In vivo chromatin immunoprecipitation (ChIP) assays from mouse livers were performed by Active Motif. Briefly, genomic DNA regions of interest were isolated using antibodies against H3K9Ac (Active Motif), RNA Pol II (Active Motif), ChREBP (Novus), and PPARα (Santa Cruz Biotechnology). qPCR reactions were carried out in triplicate using SYBR Green Supermix (Bio-Rad) on a CFX Connect Real Time PCR system. Positive and negative control sites were tested for each factor as well as the sites of interest. The resulting signals were normalized for primer efficiency by carrying out qPCR for each primer pair using input DNA (pooled unprecipitated genomic DNA from each sample). Specific enrichment was expressed as percentage of input. Further details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

In vitro ChIP assays from cultured hepatocytes were performed as described previously ([@bib35]). Briefly, genomic DNA regions of interest were isolated using antibodies against ChREBP (Novus) and immunoglobulin G (IgG) (Cell Signaling). DNA fragments were quantified by qPCR using primers described in [Table S1](#mmc1){ref-type="supplementary-material"}. Results are expressed as fold enrichment. Further details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

FAIRE-qPCR {#sec4.6}
----------

FAIRE-qPCR was performed in *Pparα*^hep+/+^ and *Pparα*^hep−/−^ hepatocytes using a protocol previously described ([@bib42]). Briefly, cells were treated with 1% formaldehyde at room temperature for 5 min to form DNA-protein crosslinks, and the crosslinking was stopped by addition of glycine to a final concentration of 125 mM. FAIRE was analyzed by qPCR on genomic DNA using the ChoRE *Fgf21* primers ([Figure 5](#fig5){ref-type="fig"}C) and calculated using relative enrichment for each amplicon using the comparative Ct method, such that a ratio is calculated for the signal from the FAIRE sample relative to the input control DNA signal. Results are expressed as fold enrichment. Experimental details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Gene Expression Analysis {#sec4.7}
------------------------

Total cellular RNA was extracted using the SV total RNA isolation system (Promega). For qPCR analysis, total RNA samples (2 μg) were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Primers for SYBR green assays are presented in [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Primers used to measure *Chrebp* expression were designed to detect the *Chrebp*α and *Chrebp*β isoforms. A specific primer to detect only the β isoform was also used. Primers for *Vnn1*, *Cyp4a10*, and *Cyp4a14* were previously described ([@bib36]). Amplifications were performed on an ABI Prism 7300 Real Time PCR System (Applied Biosystems). qPCR data were normalized by TATA-box binding protein (TBP) mRNA levels or 18S ribosomal (18S) for human samples and analyzed with LinRegPCR.22.

Transcriptomic profiles were obtained using Agilent SurePrint G3 Mouse V2 GE 8x60K (Design 074809) following the manufacturer's instructions. Data were analyzed with R (<http://www.r-project.org>) using Bioconductor packages (<http://www.bioconductor.org>, v 2.12; [@bib15]) as described in GEO: [GSE26728](ncbi-geo:GSE26728){#intref0035}. A model was fitted using the limma lmFit function ([@bib47]). Correction for multiple testing was applied using a false discovery rate ([@bib4]). Probes with adjusted p ≤ 0.05 were considered differentially expressed (n = 6). Hierarchical clustering was applied and the differentially expressed probes using 1 − Pearson correlation coefficient as distance and Ward's criterion for agglomeration. The resulting dendrogram were illustrated as a heatmap. The enrichment of gene ontology (GO) biological processes was evaluated using a conditional hypergeometric test (GOstats package; [@bib12]).

Western Blotting Analysis {#sec4.8}
-------------------------

Proteins from hepatocytes and liver tissue were extracted from whole-cell lysates. Proteins were subjected to 10% SDS-PAGE gels and transferred to nitrocellulose membranes. Rabbit polyclonal ChREBP (1:1,000, Novus Biologicals) and L-PK (1:1,500, a gift from Dr. Axel Kahn) antibodies were used. Protein β-actin (1:5,000) (Cell Signaling Technology) was used to normalize data.

Analytical Analysis {#sec4.9}
-------------------

Blood glucose was measured from total blood using an Accu-Check glucometer (Roche). Liver triglycerides were measured with a colorimetric diagnostic kit (Triglycerides FS, Diasys). Serum insulin concentrations were determined using a rat insulin ELISA assay kit (Crystal Chem) with a mouse insulin standard. The mouse ELISA kit (Millipore) was used to measure FGF21 in cell culture medium (30 μL of medium was used) and mouse plasma (20 μL).

Statistical Analysis {#sec4.10}
--------------------

Data represent at least three independent experiments, are reported as means ± SEM, and were analyzed with analysis of variance using Prism 5.0 (GraphPad) software. A Student's t test was used when comparing two groups (followed by Mann-Whitney post hoc test) or two-way ANOVA when comparing three or more groups followed by a Bonferroni post hoc test. Statistical significance was defined as p \< 0.05.
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